冬凌草甲素对人食管鳞癌细胞系KYSE-150和KYSE-450增殖及迁移的影响

目的 探讨冬凌草甲素（ORI）对食管鳞癌细胞系KYSE-150和KYSE-450增殖、凋亡、周期及迁移的作用。 方法 MTT法检测ORI对食管癌细胞增殖的影响;集落形成实验检测ORI对集落形成的影响;流式细胞术检测ORI对食管癌细胞凋亡和周期的影响;Transwell迁移实验检测ORI对食管癌细胞迁移的作用;Western blotting检测ORI对抗凋亡蛋白Bcl-2、细胞周期抑制蛋白p21Cip1/Waf1及上皮-间质转化（EMT）标志蛋白表达水平的影响。 结果 ORI对KYSE-150和KYSE-450细胞的增殖、迁移和集落形成有显著的抑制作用（P<0.05）,且抑制作用呈一定的时间、剂量依赖性;流式结果显示,随着ORI浓度的增加,细胞的凋亡率明显增加（P<0.05）,G₂/M期细胞比例显著增加（P<0.05）,G₀/G₁期细胞比例明显下降（P<0.05）;ORI处理食管癌细胞48 h,Bcl-2、间质细胞标志蛋白,波形蛋白（vimentin）、β-连环蛋白（β-catenin）表达下调,p21Cip1/Waf1、上皮细胞标志蛋白,E-钙黏蛋白（E-cadherin）表达上调。 结论 冬凌草甲素可能通过诱导细胞凋亡,阻滞细胞在G₂/M期抑制食管癌细胞的增殖,并通过抑制EMT转化从而抑制食管癌细胞的迁移。     

TLR9的激活对食管鳞癌细胞的增殖侵袭能力及NF-κB表达的影响

目的探索Toll样受体9(Toll-like receptor 9,TLR9)的激活对食管鳞癌细胞的增殖侵袭能力及NF-κB表达的影响。方法流式细胞术检测TLR9在食管鳞癌细胞TE-3、TE-13、TE-15、TE-30中的表达;免疫荧光法检测TLR9在TE-13细胞中的表达;用CpG寡脱氧核苷酸(CpG-ODN)激活TE-13,实验分为阴性对照组(control)、低剂量CpG-ODN组(1μg/mL)、中剂量CpG-ODN组(3μg/mL)和高剂量CpG-ODN组(12μg/mL)。RT-qPCR检测食管鳞癌细胞TE13中TLR9和NF-κB mRNA相对表达量的变化;采用CCK-8和Transwell法分别检测TLR9的激活对TE-13细胞增殖和侵袭能力的影响。结果①TLR9在TE-13表达量高于其他3种食管鳞癌细胞系。②3、12μg/mL CpGODN作用后TE-13细胞中TLR9被充分激活并且上调NF-κB的表达,TLR9和NF-κB的表达显著均高于阴性对照组(P0.05);低剂量CpG-ODN组与阴性组相比差异无统计学意义(P0.05)。③CCK-8和Transwell法检测发现CpGODN浓度在3、12μg/mL时TLR9的激活可显著增加TE-13细胞的增殖和侵袭能力(P0.05),激活作用具有浓度依赖性。低剂量CpG-ODN组与阴性组相比差异无统计学意义(P0.05)。结论 CpG-ODN可通过TLR9/NF-κB促进食管鳞癌细胞的增殖和侵袭,提示TLR9可能是治疗食管鳞癌的重要靶点。     

LINC00659靶向miR-149-5p调控食管鳞癌细胞Eca-109的增殖、迁移、侵袭及放射敏感性

目的 探讨长基因间非编码RNA 00659(LINC00659)是否靶向miR-149-5p调控食管鳞癌Eca-109细胞的增殖、 迁移侵袭及放射敏感性.方法 实时定量PCR(RT-qPCR)分析30对食管鳞癌组织、 对照组织中LINC00659和miR-149-5p表达量.将Eca-109细胞分为si-NC组、si-...     

食管癌细胞放射诱导前后化疗敏感性变化及相关机制研究

目的： 探讨食管癌细胞放射诱导前后对化疗药物敏感性及耐药基因ERCC1表达的变化，分析ERCC1的表达与化疗敏感性变化的关系。方法: 采用［60Co］-γ射线反复多次照射食管癌细胞株EC9706，建立放射抗拒食管癌细胞株EC9706-R。MTT法测定EC9706和EC9706-R对顺铂的IC₅₀,计算耐药指数。免疫细胞化学(SP)和RT-PCR法测定ERCC1蛋白和mRNA在2种细胞中的表达。结果: EC9706细胞对顺铂的IC50是(1.480±0.012) mg/L，EC9706-R细胞的IC₅₀是1.836±0.008 mg/L(P<0.05)，耐药指数为：1.240±0.015；ERCC1蛋白在2种细胞中染色强度指数分别为2.838±0.055和2.898±0.039，两者无统计学差异(P>0.05)。ERCC1在这2种细胞中mRNA表达的特异性基因条带与β-actin基因条带的密度比值分别为：1.168±0.068和1.143±0.089（P>0.05）。结论: 诱导建立的食管癌放射抗拒细胞较亲本细胞的化疗敏感性下降,而耐药基因ERCC1的表达水平不随细胞对放化疗敏感性的变化而变化。     

微小RNA-21与非小细胞肺癌关系的研究新进展

miRNA-21,简称miR-21,是miRNA家族的重要成员之一。近来研究发现,miR-21与非小细胞肺癌(non-small cell lung cancer,NSCLC)的预后、转移和诊断等密切相关,推测其可作为NSCLC临床诊治的新靶标。本文就miR-21与非小细胞肺癌的相关研究新进展进行综述。     

慢病毒介导的mcl-1-shRNA对食管癌细胞生长和化疗敏感性影响

目的观察慢病毒介导的shRNA沉默mcl-1基因对食管癌细胞生长作用以及化疗敏感性影响。方法利用已构建的携带mcl-1-shRNA的慢病毒载体lenti-mcl-1-shRNA感染食管癌细胞EC9706细胞系,应用RT-PCR和Western blot技术检测其对食管癌细胞mcl-1表达水平的影响;应用MTT和流式细胞技术检测其对食管癌细胞的生长作用、增殖和凋亡及化疗敏感性影响。结果感染慢病毒lenti-mcl-1-shRNA后,mcl-1 mRNA和蛋白表达水平明显下降;MTT结果显示,重组慢病毒lenti-mcl-1-shRNA可以有效抑制EC9706细胞的生长增殖,抑制率为50%,明显高于对照组(P<0.05)。流式细胞分析显示,mcl-1-shRNA可以诱导EC9706细胞凋亡,从而影响食管癌细胞的生长。另外与对照组相比,感染重组慢病毒lenti-mcl-1-shRNA后,可以明显增加顺铂对食管癌细胞的生长抑制率,提高药物敏感性(P<0.05)。结论慢病毒载体lenti-mcl-1-shRNA可有效抑制mcl-1在食管癌细胞中的表达,诱导细胞凋亡,抑制细胞生长增殖,并增加食管癌细胞对顺铂的药物敏感性。     

微小RNA-27a在子宫颈癌中的表达变化及作用机制

目的 探讨微小RNA（miR)-27a靶向调控F框/WD-40域蛋白7（FBXW7）对子宫颈癌细胞的增殖、凋亡及侵袭的影响。 方法 30例宫颈癌组织和癌旁组织、30例正常宫颈组织新鲜标本用于实验。Real-time PCR检测宫颈癌、癌旁组织、正常宫颈组织以及宫颈癌细胞（SiHa、Caski、HeLa、HCC94）、子宫颈鳞状上皮永生化细胞H8中miR-27a的表达。应用脂质体转染法将miR-27a抑制剂（inhibitor）及其阴性对照转染至SiHa细胞,CCK-8法、流式细胞术、Transwell法分别检测miR-27a对SiHa细胞增殖活性、细胞周期、凋亡率和侵袭能力的影响。生物学信息法预测miR-27a的靶向基因,双荧光素酶报告基因实验结合Western bloting验证miR-27a对FBXW7的靶向调控作用。 结果 与癌旁组织和正常宫颈组织相比,宫颈癌组织中miR-27a高表达（P<0.05）;与子宫颈鳞状上皮永生化细胞H8相比,宫颈癌细胞SiHa、Caski、HeLa、HCC94中miR-27a高表达（P<0.05）。抑制SiHa细胞中miR-27a的表达,能够明显降低细胞的增殖活性（P<0.05）,提高G0/G1期细胞比例（P<0.05）,降低S期和G2/M期细胞比例（P<0.05）, 提高细胞凋亡率（P<0.05）,抑制细胞的侵袭能力（P<0.05）。生物学信息法预测FBXW7可能是miR-27a的靶向调控基因;双荧光素酶报告基因实验显示,miR-27a可以与FBXW7基因的3’UTR区特异性结合（P<0.05）, 并负调控FBXW7蛋白的表达（P<0.05）。 结论 MiR-27a在宫颈癌的发生发展中起着癌基因的作用,抑制miR-27a表达能够明显抑制宫颈癌细胞的恶性生物学行为,其机制可能与靶向调控FBXW7的表达有关。     

微小RNA-3651过表达通过介导核因子κB信号通路抑制人舌癌细胞CAL27的生长与侵袭

目的 探讨微小RNA(miR)-3651过表达通过介导核因子（NF）-κB信号通路抑制人舌癌细胞CAL27生长与侵袭的机制。方法 将对数生长期CAL27细胞分为miR-3651 mimic组、mimic-NC组和对照组。采用qRT-PCR检测转染后细胞miR-3651水平,CCK-8检测细胞活力,Transwell检测细胞侵袭能力,划痕实验检测细胞迁移能力,光学显微镜下观察细胞上皮间质转化（epithelial-mesenchymal transition,EMT）的形成,Western blot检测E钙粘蛋白、N钙粘蛋白、波形蛋白、NF-κB p65和p-NF-κB p65蛋白表达。结果 mimic-NC组与对照组细胞miR-3651水平、细胞活力、侵袭细胞数、细胞迁移率和细胞形态均无明显差异（P>0.05）,E钙粘蛋白、N钙粘蛋白、波形蛋白和p-NF-κB p65/NF-κB p65蛋白表达均无明显差异（P>0.05）;与mimic-NC组相比,miR-3651 mimic组细胞miR-3651水平升高（P<0.05）,培养的细胞第2、3、4天的活力降低（P<...     

微小RNA-193a调控Wilms瘤基因1促进小鼠糖尿病肾病足细胞凋亡

目的 探讨微小RNA（miR）-193a对糖尿病肾病（DN）足细胞凋亡的影响及作用机制。 方法 通过体外高糖培养足细胞和体内小鼠腹腔注射链脲佐菌素(STZ)复制DN模型,将细胞或60只小鼠随机分为空白对照组、模型对照组、miR-193a抑制阴性对照组、miR-193a抑制组、miR-193a过表达阴性对照组和miR-193a过表达组。使用流式细胞术、免疫组织化学、免疫荧光、TUNEL、Real-time PCR和Western blotting检测DN小鼠和小鼠足细胞凋亡情况。 结果 DN小鼠和高糖诱导的小鼠足细胞中Nephrin、Podocin表达减弱,细胞凋亡率显著升高,miR-193a高表达,小鼠肾脏和足细胞中cleaved-Caspase-3和Bax蛋白水平显著升高,Bcl-2蛋白水平显著下降,而miR-193a 抑制剂(inhibitor)可改善这一过程。DN小鼠和高糖培养的小鼠足细胞中Wilms瘤基因1（WT1） mRNA和蛋白表达水平显著降低,miR-193a inhibitor干预后WT1蛋白表达显著升高。上调WT1可降低miR-193a对高糖诱导的小鼠足细胞凋亡的影响。双荧光素酶报告实验证实了miR-193a和WT1之间的靶向关系。 结论 MiR-193a下调WT1的表达,促进DN足细胞凋亡。     

微RNA-21与血清肿瘤标志物癌胚抗原、神经特异性烯醇化酶及CYFRA21-1对非小细胞肺癌预后预测的临床价值分析

探讨微RNA-21（miR-21）与癌胚抗原（CEA）、神经特异性烯醇化酶(NES)及CYFRA21-1对非小细胞肺癌（NSCLC）预后预测的临床价值。NSCLC患者确诊时已经错过最佳手术时间,化疗成为最主要的治疗手段,但患者生存率并未得到明显提升。实验室血清学指标检测具有样本易获得、操作方便、价格低廉、无创伤以及可连...     

A new in vitro model for analyzing the biological behavior of well-differentiated squamous cell carcinoma

A suitable model analyzing the behavior of well-differentiated squamous cell carcinoma has not yet been established. We tried to establish such a system using a reconstructed oral mucosa, in which T3M-1 squamous cell carcinoma cells were cultured on 3T3 fibroblast-containing collagen gel. Fibroblasts promoted the stratification and keratinization of T3M-1 cells. During growth, the Ki-67 index of T3M-1 cells with fibroblasts was higher than that of T3M-1 cells alone. Fibroblasts increased the expression of involucrin, a differentiating marker of keratinocytes, in T3M-1 cells. They also promoted the invasion of T3M-1 cells into the gel. When T3M-1 cells alone were cultured in a fibroblast-conditioned (FC) medium, the fibroblast-induced phenomena mentioned above were almost replicated. In addition, epidermal growth factqr (EGF) promoted T3M-1 cells growth, but not the invasion. cDNA microarray analysis showed that FC medium increased the expression of EGF receptor and several other mRNAs of T3M-1 cells. The data suggest that T3M-1 cells, under cancer-stromal fibroblast interaction, undergo invasive growth with their well-differentiated squamous phenotype, and that this interaction may be mediated partly by soluble molecules (e.g., EGF) in an autocrine or paracrine pathway. Our system will probably provide a useful model for analyzing the biological behavior of well-differentiated squamous cell carcinoma.     

Long noncoding RNA PANDA promotes esophageal squamous carcinoma cell progress by dissociating from NF-YA but interact with SAFA

Esophageal squamous cell carcinoma (ESCC) is one of the major global health problems, especially in Asia. Long non-coding RNAs (lncRNAs) have been increasingly identified and characterized in almost every aspect of biology, especially in cancer biology. This research desires to explore the regulatory mechanism of lncRNA PANDA (PANDA) on ESCC process. Quantitative real-time PCR (qRT-PCR) was carried out to detect the PANDA expression, which was up-regulated in matched cancerous tissues and adjacent noncancerous tissues from 134 patients and 9 ESCC cell lines. Higher expression of PANDA in ESCC tissues was associated with TNM stage, advanced clinical stage, and shorter overall survival of ESCC patients by MTT, EDU, colony formation assay and flow cytometry in KYSE180 and KYSE450 cells. Exogenous down-regulation of PANDA expression significantly suppressed ESCC cells proliferation and colony formation by arresting G1-S checkpoint transition in vitro, and retarded the development of tumors in vivo. Meanwhile, qRT-PCR and western blot assays showed that depletion of PANDA reduced E2F1, cyclinD1, cyclinD2, cyclinE1 and Bcl-2 expression. RIP showed the interaction between PANDA and NF-YA or SAFA. Our findings suggested that, PANDA drifted away from NF-YA to promote the expression of NF-YA-E2F1 co-regulated proliferation-promoting genes, and to limit the cell apoptosis. In addition, PANDA binds SAFA to switch on the tumor proliferation program through CyclinD1/2-Cyclin E1 and Bcl-2 pathways. PANDA could serve as a potential prognostic biomarker and therapeutic target for ESCC.     

Altered expression and localization of desmoglein 3 in esophageal squamous cell carcinoma

Desmoglein 3 (DSG3), a transmembrane cadherin of the desmosomal cell–cell adhesion structure, plays vital roles in the maintenance of normal epithelial tissue architecture. Reports implicating a role for DSG3 expression in cancer are few and contradictory. In this study, immunohistochemical staining was employed to investigate DSG3 expression and subcellular localization in esophageal squamous cell carcinoma (ESCC), and to correlate changes with clinical characteristics. Results indicate that in normal squamous cell epithelia, strong DSG3 immunoreactivity was observed in the Stratum spinosum, and localization occurred only at the cell membrane. In ESCC, DSG3 immunoreactivity displayed an abnormal cytoplasmic localization that was correlated with cell differentiation (P = 0.018). Most strikingly, in 74.1% of the tumors, DSG3 expression was up-regulated and correlated with regional lymph node metastasis (P = 0.036). Moreover, in patients without lymph node metastasis, cytoplasmic localization of DSG3 correlated with poor prognosis (P = 0.044). These results suggest that DSG3 is involved in the development of ESCC and imply that DSG3 overexpression is likely to be an essential contributor to the aggressive features of esophageal cancer.     

Association of Kruppel-like factor 4 expression with the prognosis of esophageal squamous cell carcinoma patients

Objective: To investigate the association of Kruppel-like factor 4 (KLF4) expressions with the prognosis of esophageal squamous cell carcinoma (SCC) patients. Methods: Ninety-eight cases of esophageal carcinoma patients were enrolled. The expression of KLF4 in the esophageal SCC and normal esophageal mucosa tissues were examined by immunohistochemistry. The correlations between the expression of KLF4 protein and patients’ clinical characteristics and prognosis were analyzed. Results: We observed higher expressed KLF4 in normal esophageal mucosa tissues than esophageal SCC tissues, with positive rate of 82.7% (81/98) and 43.8% (43/98) respectively. In patients with lymphatic metastasis, the positive rate of KLF4 was 24.4% (10/41), whereas it was 57.9% (33/57) in patients without lymphatic metastasis, and the difference was significant (x² = 10.871, P = 0.001). The positive rates of KLF4 were 62.5% (5/8), 53.1% (26/49) and 29.3% (12/41) in stage I, II and III patients, respectively. There were no correlations between the expression of KLF4 and gender, age, tumor size, location, differentiation grade and infiltration depth. The 5-year survival rates and median survival times were 48.8% and 25.5%, and 55 and 26 months for the patients with KLF4 positive and negative expression, respectively. There were significant differences between the patients with KLF4 positive expression and negative expression in the 5-year survival rates and median survival times (x² = 5.747 and 4.493, P = 0.017 and 0.034). Conclusion: KLF4 might act as a tumor suppressor in esophageal SCC and the expression status of KLF4 could be considered as a prognosis predictor for esophageal SCC patients.     

食管鳞癌预后因素的病理学和免疫组织化学研究

目的 探讨食管癌组织病理学特征和免疫蛋白表达的预后价值。方法 检测９７例原发性食管鳞癌手术切除标本,对肿瘤组织病理学特征和免疫蛋白表达与患者生存期的关系进行单因素Ｋａｐｌａｎ Ｍｅｉｅｒ分析和多因素Ｃｏｘ分析。结果 单因素Ｋａｐｌａｎ Ｍｅｉｅｒ分析显示,低分化肿瘤、浸润性生长、肿瘤侵及外膜、间质无淋巴细胞浸润、淋巴结转移、高ＴＮＭ分期、表皮生长因子受体（ＥＧＦＲ）阳性表达和ｎｍ２３阴性表达与患者     

CD51 is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma

Background

Esophageal squamous cell carcinoma (ESCC) is a common cancer in East Asia and some other parts of the world with a dismal prognosis. CD51 (integrin αv),a transmembrane glycoprotein responsible for cell-to-matrix binding has been found to enhance tumor progression. However, its expression and clinicopathological significance in ESCC tumors are not fully understood. The purpose of this study was to investigate the expression level of CD51 and to explore its clinicopathological significance in ESCC.

Association of p53 expression with prognosis in patients with esophageal squamous cell carcinoma

It has been well accepted that p53 overexpression is associated with advanced stages of cancer. However, the prognostic role of p53 overexpression in esophageal squamous cell carcinoma (ESCC) remains unclear. To investigate the prognostic role of p53 overexpression in patients with ESCC, a retrospective cohort study of 136 ESCC patients was carried out. The expression of p53 protein in tumor tissues was investigated immunohistochemically. Positive expression of p53 protein was detected in 57 ESCC patients (41.9%). The p53 overexpression was associated with smoking (P < 0.001), tumor differentiation (P < 0.001), and tumor size (P < 0.001). In the Kaplan-Meier analysis, patients with p53 overexpression had significantly shorter overall survival than those patients with negative p53 expression (log-rank P < 0.001). Multivariable analysis by Cox regression model further showed that p53 overexpression was a significantly independent predictor of poorer overall survival (hazard ratio [HR] = 1.91; 95% confidence interval [95% CI] 1.03-3.54, P = 0.04). Thus, p53 overexpression is associated with poor prognosis in patients with early stage esophageal squamous cell carcinoma, and it’s a significantly independent predictor of poorer overall survival.     

Prognostic value of osteopontin expression in esophageal squamous cell carcinoma: A meta-analysis

ObjectiveTo explore the prognostic role of osteopontin (OPN) overexpression in esophageal squamous cell carcinoma (ESCC).MethodsThe PubMed, EMBASE, The Cochrane Library, China National Knowledge Infrastructure, Wanfang, Chinese Biomedical Data (CBM) and VIP databases were searched from the establishment dates of the databases to March 31, 2019, for potentially related studies. Stata 12.0 software was used for statistical analyses, and the hazard ratios (HRs) with 95% confidence intervals (CIs) were combined to assess the correlation of OPN overexpression with the overall survival (OS) and progression-free survival (PFS) of ESCC patients.ResultsA total of 8 studies involving 811 patients from China or Japan were included. OPN overexpression was demonstrated to be significantly associated with poor OS (HR = 1.86, 95% CI: 1.22–2.83, P = 0.004), with high heterogeneity (I² = 61.2%, P = 0.012), and poor PFS (HR=1.63, 95% CI: 1.08–2.47, P = 0.020), without heterogeneity (I² = 0.0%, P = 0.839). Subgroup analysis results were similar to the pooled results.ConclusionOPN overexpression might serve as a promising independent prognostic risk factor in Chinese and Japanese ESCC patients. However, more well-designed studies enrolling more patients are still needed to verify our findings.